Antibiotic
Pfizer introduces Spectramast LC (ceftiofur hydrochloride), an intramammary infusion indicated for the treatment of mastitis caused by Gram-negative and Gram-positive bacteria.
Pfizer introduces Spectramast LC (ceftiofur hydrochloride), an intramammary infusion indicated for the treatment of mastitis caused by Gram-negative and Gram-positive bacteria.
The product shows efficacy against Escherichia coli, coagulase-negative staphylococci and Streptococcus dysgalactiae.
"We're excited to bring a new product to a market that hasn't seen an innovative, new mastitis treatment in more than 10 years," says Austin Belschner, DVM, MS, manager dairy veterinary operations, Pfizer Animal Health.
Spectramast LC has a zero-day, pre-slaughter meat withdrawal, which is the shortest withhold time of any available mastitis treatment, allowing greater flexibility and more management options.
Once-a-day dosing and a 72-hour milk withhold time round out the product's benefits, the company says.
The product is sold in 10-mL disposable syringes that contain 125-mg of ceftiofur.
The product can be stored at a controlled room temperature.
For fastest response, visit
